INTRODUCTION
Vitamin D deficiency is implicated in the etiology of several common diseases, including cancer. 1 Colorectal cancer (CRC) is the third most frequent cancer worldwide, with an estimated 1.2 million cases or more and 600,000 deaths annually, and yet it is potentially largely preventable. 2 Worldwide, there is substantial variation in CRC incidence (10-fold) and mortality (six-fold) 2 that may be attributable to different vitamin D levels between populations. 3 Dietary vitamin D intake is generally low, even in those taking supplements. 4, 5 Hence, skin synthesis during exposure to sunlight (ultraviolet B) is the major source of vitamin D. Such synthesis is profoundly influenced by geographical latitude and meteorologic factors. Modern lifestyle further compounds any deficit, because daylight hours are increasingly spent indoors. Thus, maintaining sufficient vitamin D levels is severely compromised, particularly in northern latitudes.
Establishing a causal relationship between CRC incidence and vitamin D deficiency is challenging because environmental risk factors associated with CRC may also be associated with vitamin D deficiency (co-causality; eg, level of physical activity), the presence of a tumor and its treatment may actually deplete vitamin D (reverse causation): decreased circulating 25-hydroxyvitamin D (25-OHD) concentration has been reported after elective knee surgery, 6 and voluntary or involuntary changes in a patient's diet and lifestyle, such as being bed-bound or suffering fatigue, may decrease time spent outdoors and have further impact on 25-OHD levels. Evidence from studies investigating the relationship between CRC risk and exposure to solar radiation and vitamin D intake and/or circulating levels supports an inverse relationship between vitamin D and risk. 7, 8 Moreover, interaction between vitamin D level and functional sequence variants at the vitamin D receptor (VDR) gene locus also influence CRC risk.
9,10
The relationship between vitamin D and CRC mortality is even less well understood. An ecological study published more than 30 years ago was the first to report an inverse relationship between CRC mortality and exposure to solar radiation.
11 Similarly, better survival in patients diagnosed during summer and fall was shown more recently. 12 These provide circumstantial evidence linking vitamin D levels with cancer outcome. Higher intake of dietary vitamin D 13 and higher circulating levels of 25-OHD 13-17 have also been linked to better survival after CRC diagnosis. However, published work used proxies for plasma vitamin D level in patients with cancer (season of diagnosis, ultraviolet B intensity, dietary vitamin D). Prediagnostic plasma 25-OHD level that has been associated with cancer survival seems unlikely to reflect vitamin D level in the period following diagnosis, surgery, and chemotherapy. Predicted vitamin D level at diagnosis (from assays performed years before diagnosis) also suggests an association between low levels and poor CRC survival outcome. 16 In this study, we investigated whether circulating vitamin D concentration influences survival after surgical intervention for CRC. We directly assayed total 25-OHD, which reflects both dietary intake and skin synthesis of vitamin D. 18, 19 To mitigate against potential confounding effects due to reverse causation, thereby implicating a causal relationship, we tested for interaction between plasma vitamin D level and genotype at the VDR locus.
PATIENTS AND METHODS

Study Population and Follow-Up
The Study of Colorectal Cancer in Scotland (SOCCS) is a prospective, population-based case-control study designed to identify genetic and environmental factors that have an impact on CRC risk and survival outcome. 20 All participants provided informed written consent, and research was approved by the MultiCentre Research Ethics Committee for Scotland, local research ethics committees, and National Health Service management. In this study, we measured 25-OHD plasma levels in 1,598 patients with stage I to III CRC who underwent surgical resection with curative intent and for whom we collected detailed clinical, pathologic, dietary, and lifestyle information.
Follow-up was through systematic search of the Scottish national records system. Deaths were ascertained through linkage to National Records of Scotland. Primary cause of death (CRC, other cancer, other cause) was assigned from death certificates separately by two researchers (L.Z., F.V.N.D; Ͼ 99% concordance). Follow-up was calculated as time between blood sampling and death or between sampling and censor date (January 31, 2013) for patients who were not known to have died.
Plasma Vitamin D Assay
To minimize technical variability, all plasma samples were batched, and 25-OHD was assayed to a standardized protocol in the same laboratory. Total 25-OHD (25-OHD 2 and 25-OHD 3 ) was measured by liquid chromatographytandem mass spectrometry. 21 To account for seasonal differences, 25-OHD concentration was May-standardized by adjusting for sampling month using differences in age-and sex-adjusted monthly averages generated from SOCCS control participants. 4 May-adjusted measurements were used in analyses throughout, unless otherwise specified.
Vitamin D deficiency is defined in terms of circulating 25-OHD as vitamin D deficient (Ͻ 10 ng/mL), at high (10 to 16 ng/mL) or low (16 to 20 ng/mL) risk of deficiency, or as vitamin D sufficient (Ͼ 20 ng/mL), although these thresholds are subject to debate. 4, 18 Because few individuals in Scotland are vitamin D sufficient, 4 we grouped patients into 25-OHD tertiles to maximize statistical power. Vitamin D intake was calculated from a food frequency questionnaire. 
Genotype at the VDR Locus
Blood leukocyte DNA was genotyped for polymorphisms at the VDR gene locus (rs1544410, rs10735810, rs7975232, rs11568820) by using either an Illumina Infinium array or DNA sequencing. Protective allele score was calculated by summing the following: rs10735810 G allele, 22 a variant that determines the translational start site and downstream 1,25-dihydroxycholecalciferol (1, 25 [OH] 2 D) effects 23 ; rs1544410 T allele, a variant that has been associated with increased VDR mRNA expression and increased serum levels of 1,25(OH) 2 D 24 ; and rs11568820 A allele, a variant that is located in the VDR promoter region and directly influences transcriptional activity. 25 rs7975232 has been excluded, given high correlation with rs1544410 (r 2 ϭ 0.63 in the United Kingdom; 2 P Ͻ .001 in this cohort).We estimated VDR phased haplotypes for the four genotyped VDR polymorphisms for all samples by using BEAGLE software (version 3.3.2) with standard settings. 26 BEAGLE builds a model of haplotypes from which it identifies likely haplotypes that underlie the genotype data. The resulting haplotypes were tabulated so that each sample was assigned two haplotypes. Accordingly, variables corresponding to the dose of each haplotype were created. For each haplotype, we set the dose to give values of 0 (haplotype not present), 1 (heterozygous), or 2 (homozygous), with the sum of haplotype doses equaling 2 for any individual.
Given sample size constraints, we considered only haplotypes with frequencies of more than 10% and included them as dose variables in the adjusted Cox proportional hazards regression models (rarer haplotypes were ignored). We first ran models that investigated main effects of VDR haplotypes and then extended the models to include interaction terms between VDR haplotypes and May-adjusted vitamin D tertiles.
Patient-and Tumor-Related Variables
We considered factors with an established contribution to CRC mortality or etiology, including sex; smoking; physical activity; family history; nonsteroidal anti-inflammatory drugs; total daily energy; red meat, calcium, and alcohol intake; and socioeconomic status. 20 We collected detailed information on tumor site and multiplicity and clinicopathologic staging from clinical records and tumor boards (Scottish Managed Clinical Networks). Preoperative imaging was collected from participating centers. By using collated pathology, imaging, and clinical data, tumor stage was assigned according to the Union for International Cancer Control TNM staging system and was mapped onto the American Joint Committee on Cancer (AJCC) staging system (AJCC stage I to IV). AJCC stage IV was excluded from the analysis of vitamin D effect on survival.
Surgery and Chemotherapy
Date of definitive treatment is the date of surgical treatment. Extent of surgery was recorded (as polypectomy and/or local excision or resection). All patients were treated with curative intent, so any chemotherapy was administered in the adjuvant setting. We assessed whether chemotherapy modified associations between 25-OHD concentration and mortality in stage II and III disease in a subset of patients for whom these data were available (n ϭ 758; chemotherapy administered to 365 patients). 
Time to Sampling
Statistical Analysis and Survival
Data were analyzed by using R program and survival package for R. The associations between circulating vitamin D and patient characteristics were investigated by one-way analysis of variance or by 2 test for categorical variables. We first examined the association between vitamin D and CRCspecific and all-cause mortality by using Kaplan-Meier survival analysis. Cox proportional hazards models were used to calculate hazard ratios (HRs), adjusting the analysis for other relevant factors. Test of the proportional hazards assumptions was performed. HRs were calculated for vitamin D tertiles, with the lowest category as the reference. To explore effect modification, we assessed the risk in an analysis stratified for cancer stage. Trend tests were calculated based on 25-OHD as a continuous variable. P Ͻ .05 was considered statistically significant unless otherwise stated. Main effects of VDR polymorphisms and haplotypes and their multiplicative interaction with vitamin D on survival were assessed by using a Cox proportional hazards model.
Because four single nucleotide polymorphisms (SNPs) in the VDR gene were tested, the corrected P value threshold was set to .013 for this analysis.
Meta-Analysis
We searched PubMed and Cochrane Collaboration databases for studies that investigated the relationship between circulating 25-OHD and survival in patients with colorectal cancer by using search terms "25-hydroxyvitamin D", "vitamin D", "colon cancer", "colorectal cancer", "rectal cancer", "bowel cancer", "survival", and "mortality", and we hand-searched resultant bibliographic references. We identified only six relevant studies 13,16,27-30 and one recent systematic review. 31 Exclusions were as follows: two studies 13,16 reported analyses of the same patient cohort; one study 16 used predicted rather than measured 25-OHD; and another study 29 included patients with metastatic (stage IV) CRC. We performed a fixed effects meta-analysis of our data with that from the four remaining studies.
13,27,28,30
RESULTS
At the time of sampling, 49.7% of patients fulfilled criteria for vitamin D deficiency (25-OHD below 10 ng/mL), and a further 26.8% were at high risk of deficiency (10 to 16 ng/mL). in the Data Supplement and according to tertiles in Table 1 . Among the 1,598 patients, there were 12,323 person-years of follow-up, 363 deaths as a result of CRC, and 168 deaths as a result of other causes (Table 1) . Median follow-up was 8.9 years (IQR, 6.0 to 9.9 years) overall and 9.6 years (IQR, 8.8 to 10.2 years) for those alive at censor date. Median survival time by stage for patients who died as a result of CRC was 5.5 years (IQR, 3.6 to 7.4 years; n ϭ 28) for stage I, 3.4 years (IQR, 2.1 to 5.6 years; n ϭ 110) for stage II, and 2.7 years (IQR, 1.6 to 4.5 years; n ϭ 227) for stage III patients (Data Supplement).
Mortality
Higher postoperative 25-OHD levels were strongly associated with lower CRC-specific (P ϭ .008) and all-cause (P ϭ .003) mortality ( Table 2 ). Comparing patients with May-adjusted 25-OHD levels in the highest versus the lowest tertile, the adjusted HR was 0.68 (95% CI, 0.50 to 0.90) for CRC-specific mortality and 0.70 (95% CI, 0.55 to 0.89) for all-cause mortality. Results were consistent using unadjusted 25-OHD (Data Supplement). The effect was particularly apparent for patients with stage II disease. Comparing the highest to the lowest tertile in patients with stage II CRC, the adjusted HR was 0.44 (95% CI, 0.25 to 0.76) for CRC-specific mortality (Table 3) . CRC-specific mortality reached 10% after 2.5 years for patients in the lowest tertile (AJCC II) and after 6.6 years for patients in the highest tertile of 25-OHD (Fig 1) . Trends were similar for all-cause mortality (Data Supplement).
Analysis of deficiency categories (Ͻ 10, 10 to 16, 16 to 20, and Ͼ 20 ng/mL) gave results consistent with those using tertiles (data not shown) and when we calculated follow-up from incidence instead of sampling date adjusting for survival before sampling.
Adjuvant Chemotherapy
The protective effect of higher 25-OHD levels was stronger for patients not receiving chemotherapy (disease stage II and III) than for those receiving chemotherapy (lowest v highest tertiles; HR, 0.42; 95% CI, 0.22 to 0.80; P ϭ .008; P trend ϭ .006). Again, the effect size was most prominent in stage II disease (HR, 0.34; 95% CI, 0.14 to 0.81; Data Supplement).
Meta-Analysis
In multivariable analysis, each study showed either an association between lower mortality and higher 25-OHD levels or a nonsignificant trend with the same direction of effect (Data Supplement). In a meta-analysis of four published studies and our data, adjusted HR for CRC-specific mortality was 0.67 (95% CI, 0.54 to 0.81), and it was 0.65 (95% CI, 0.55 to 0.77; Data Supplement) for all-cause mortality.
Genotype and Haplotypes at the VDR Locus
There was no association between survival and VDR SNPs individually or with protective allele score (Table 4 ). However, there was evidence for gene-environment interaction effects on CRC-specific mortality between May-adjusted 25-OHD level and rs11568820 genotype (P ϭ .008) and also protective allele score (P ϭ .004; Table 4 and Data Supplement for all-cause mortality). A trend toward a reduction in cancer mortality was observed for a majority of genotype subgroups (Table 5) . Interestingly, if the number of protective alleles was low (two or fewer), adjusted HR for the highest tertile of May-adjusted 25-OHD was highly significant (HR, 0.46; 95% CI, 0.33 to 0.70; P Ͻ .001), although if there were three or more protective alleles, Mayadjusted 25-OHD was not significantly associated with survival (HR, 1.01; 95% CI, 0.65 to 1.58). Notwithstanding that dietary history is an imprecise measure of vitamin D intake, we observed a suggestive interaction between intake and rs11568820 genotype (adjusted P ϭ .09 for CRC-specific mortality; unadjusted P ϭ .11).
Analysis of haplotypes with frequencies of more than 10% is shown in the Data Supplement. In the adjusted Cox proportional hazards model, there was no association between haplotype dose NOTE. Multivariate model adjusted for age at diagnosis, sex, American Joint Committee on Cancer stage, tumor site (colon/rectum), surgery (yes/no), time between definitive treatment and sampling, season of blood collection, body mass index, and level of physical activity. P values that are significant at multiple testing adjusted level (P Ͻ .013) are shown in bold.
Abbreviations: 25-OHD, 25-hydroxyvitamin D; CRC, colorectal cancer; HR, hazard ratio; HWE, Hardy-Weinberg equilibrium; LD, linkage disequilibrium; SNP, single nucleotide polymorphism; VDR, vitamin D receptor.
‫ء‬
Several functional VDR gene polymorphisms were considered. rs11568820 is located in the VDR promoter region and directly influences transcriptional activity. 23 rs1544410 has been associated with increased VDR messenger RNA expression and increased serum levels of 1,25-dihydroxycholecalciferol. 24 rs1544410 is in high LD with rs7975232, and both are located in an intron and so may tag a causal variant rather than affect VDR function directly. There were no deviations from HWE for examined SNPs.
†AA and AG genotypes were analyzed jointly because of the low frequency of AA genotype (5.4%). In the analysis in which the three genotypes were kept separate, P ϭ .03 for the interaction with unadjusted 25-OHD, and P ϭ .016 for the interaction with May-adjusted 25-OHD.
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www.jco.org (alone) and survival (Data Supplement). However, after including an interaction term in the model, there was an interaction between dose of GAGC haplotype and May-adjusted vitamin D. This interaction was highly significantly associated with overall survival, even after accounting for multiple testing (P ϭ .008).
DISCUSSION
In this prospective cohort study of 1,598 patients sampled after treatment for stage I to III CRC, we show that higher plasma 25-OHD level is associated with lower cancer-specific and all-cause mortality. We assayed plasma total 25-OHD, the best biomarker of both dietary intake and sunlight exposure. The interaction between 25-OHD and genetic variation at the VDR locus in relation to survival provides additional evidence implicating the vitamin D pathway and provides support for a causal relationship (see the Data Supplement for a discussion of causality). The magnitude of effect was substantial and clinically important. Mortality was about one third lower in the patient group with the highest compared with the lowest plasma 25-OHD tertiles. The direction of protective effect was consistent across different strata of patients. CRCspecific mortality was 20% at 5 years in patients with the lowest plasma 25-OHD tertile, and 10 years elapsed before mortality reached 20% in those with the highest tertile. There was a similar differential in all-cause mortality between plasma tertile groups (20% mortality after 3.5 and 6.0 years). Because of Scotland's northern latitude, vitamin D deficiency is highly prevalent in the Scottish population 4 and, unsurprisingly, this is reflected in the patients with CRC studied here. However, even within this narrow, deficient range, we have shown that vitamin D has a protective effect from death after a diagnosis of CRC. This suggests that plasma 25-OHD assayed postoperatively may have utility as a biomarker for survival in patients without evidence of systemic metastases. Furthermore, the gene-environment interaction between genetic variation at the VDR locus and vitamin D level suggests that vitamin D may actively protect from death, rather than merely reflecting tumor aggression and an inevitable outcome. Although the evidence presented here linking plasma 25-OHD level with outcome is persuasive, there is now a pressing need for prospective randomized trials to establish definitively whether dietary vitamin D supplementation reduces cancer-specific and all-cause mortality following a diagnosis of CRC.
All published studies to date have a fundamental methodologic limitation: 25-OHD concentration was not determined in cancer survivors but was instead measured years before cancer diagnosis, 13, 27, 30 perioperatively, 28 or was predicted from the determinants of 25-OHD concentration. 16 We designed this study to investigate whether vitamin D deficiency contributes to survival outcome in a wellcharacterized cohort in which plasma 25-OHD was measured after CRC diagnosis and surgical treatment. Thus, to the best of our knowledge, this is the first study to examine the effect of postoperative vitamin D levels on survival in patients with CRC and the first to investigate gene-environment interaction between vitamin D level and genetic variation at the VDR gene locus.
This study has some limitations. One single measurement of 25-OHD was taken. Although this is likely to reduce statistical power, it is unlikely to bias findings. In this population, 25-OHD concentrations are generally low, preventing us from systematically examining the effect of higher concentrations. The time period between cancer treatment and 25-OHD sampling levels was not constant (although there was no detectable association between time interval to sampling and 25-OHD levels or outcome). The limited number of SNPs in the analysis may reduce the accuracy of inferred haplotypes. We cannot exclude the possibility that low 25-OHD is associated with other predictors of poor prognosis because this was an observational study. 41 in the normal mucosa of patients with colorectal adenoma, further highlighting the need to explore vitamin D as a preventative and therapeutic anticancer agent. 38 In this large study, we report for the first time an association between mortality following a diagnosis of CRC and an interaction between GAGC haplotype dose and vitamin D. Plasma 25-OHD, along with genotype at the VDR locus, has potential utility as a prognostic biomarker. In conclusion, our findings suggest a causal relationship between vitamin D and survival outcome in patients with cancer. Hence, there is now a compelling case for appropriately designed and adequately powered randomized clinical trials aimed at testing whether actively supplementing the diet of patients recently diagnosed with CRC with vitamin D can have a favorable impact on survival.
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